Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide Tetraxetan, (Lu-177)- PNT2002, Radium-223 dichloride), Target (PSMA, SSTR, Bone Metastases), Indication (Prostate Cancer, Neuroendocrine Tumors (NETS), SCLC) - Global Forecast to 2035

1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Market Segmentation and Regional Scope
1.3.2 Inclusions and Exclusions
1.3.3 Years Considered
1.4 Currency Considered
1.5 Stakeholders

2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Objectives of Secondary Research
2.1.1.2 Key Data from Secondary Sources
2.1.2 Primary Data
2.1.2.1 Breakdown of Primaries
2.1.2.2 Key Objectives of Primary Research
2.2 Market Size Estimation
2.2.1 Global Market Estimation
2.2.1.1 Company Revenue Analysis (Bottom-Up Approach)
2.2.1.2 Revenue Share Analysis
2.2.1.3 Repository Analysis
2.2.1.4 Primary Interviews
2.2.2 Insights from Primary Experts
2.2.3 Segmental Market Size Estimation (Top-Down Approach)
2.3 Growth Rate Projections
2.4 Data Triangulation
2.5 Research Assumptions
2.6 Research Limitations
2.7 Risk Analysis

3.1 Strategic Imperatives for Key Stakeholders
3.1.1 Biotech Startups and Innovative Companies
3.1.2 Established Market Leaders
3.1.3 Cdmos and Cros

4.1 Radioligand Therapy Market Overview
4.2 North America: Radioligand Therapy Market, by Product and Country, 2025
4.3 Radioligand Therapy Market: Geographic Growth Opportunities
4.4 Radioligand Therapy Market: Emerging Vs. Developed Markets
4.5 Interconnected Markets and Cross-Sector Opportunities
4.6 Emerging Business Models and Ecosystem Shift
4.7 Vc/Private Equity Investment Trends and Startup Landscape
4.8 Regulatory Policy Initiatives

5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Approvals and Label Expansion of Rlt Products
5.2.1.2 Manufacturing Scale-Up of Lu-177
5.2.1.3 Rising Adoption of Prostate-Specific Membrane Antigen and Somatostatin Receptor Pet Imaging
5.2.1.4 Expanding Reimbursement Coverage
5.2.2 Restraints
5.2.2.1 Isotope Supply Scarcity
5.2.2.2 Stringent Regulatory Requirements
5.2.2.3 Logistical Hurdles and Half-Life Constraints
5.2.3 Opportunities
5.2.3.1 Advancements in Alpha Therapies
5.2.3.2 Expansion of Radioligand Therapy into Earlier-Line and Adjuvant Settings
5.2.3.3 Combination Regimens Integrating Radioligand Therapy
5.2.4 Challenges
5.2.4.1 Reactor Outages and Geopolitical Risks
5.2.4.2 Growing Competition from Alternative Modalities
5.3 Trends/Disruptions Impacting Customer Business
5.4 Pricing Analysis
5.4.1 Indicative Pricing Analysis, by Key Player, 2024
5.4.2 Indicative Pricing Analysis, by Region
5.5 Value Chain Analysis
5.6 Ecosystem Analysis
5.7 Investment and Funding Scenario
5.8 Technology Analysis
5.8.1 Key Technologies
5.8.1.1 Beta-Emitting Therapeutic Radionuclides
5.8.1.2 Alpha-Emitting Therapeutic Radionuclides
5.8.1.3 Targeting Ligands
5.8.1.4 Monoclonal Antibody-Directed Radiotherapeutics
5.8.2 Complementary Technologies
5.8.2.1 Spect/Ct and Pet/Ct
5.8.2.2 Alternative Isotopes
5.8.3 Adjacent Technologies
5.8.3.1 Antibody Drug Conjugates
5.8.3.2 Bispecific Antibodies
5.9 Key Conferences and Events, 2025-2027
5.10 Regulatory Landscape
5.10.1 Regulatory Analysis
5.10.2 Regulatory Bodies, Government Agencies, and Other Organizations
5.11 Porter’S Five Forces Analysis
5.11.1 Bargaining Power of Suppliers
5.11.2 Bargaining Power of Buyers
5.11.3 Threat of New Entrants
5.11.4 Threat of Substitutes
5.11.5 Intensity of Competitive Rivalry
5.12 Key Stakeholders and Buying Process
5.12.1 Key Stakeholders in Buying Process
5.12.2 Buying Criteria
5.13 Macroeconomics Indicators
5.13.1 Healthcare Expenditure Trends
5.13.2 Global Cancer Burden
5.14 Pipeline Analysis
5.15 Unmet Needs and White Spaces
5.16 Impact of AI/Gen AI on Radioligand Therapy Market
5.16.1 Introduction
5.16.2 Market Potential of AI in Radioligand Therapy Applications
5.16.3 AI Use Cases
5.17 Impact of 2025 US Tariff
5.17.1 Introduction
5.17.2 Key Tariff Rates
5.17.3 Price Impact Analysis
5.17.4 Impact on Country/Region
5.17.4.1 US
5.17.4.2 Europe
5.17.4.3 Asia-Pacific
5.17.4.4 Rest of the World
5.17.5 Impact on Manufacturing Industry

6.1 Introduction
6.2 Lutetium 177 Vipivotide Tetraxetan
6.2.1 Broader Regulatory Acceptance and Expanding Payer Coverage to Aid Growth
6.3 Lutetium-177 Dotatate
6.3.1 Increasing Recognition of Lutetium-177 Dotatate in Treating Gastroenteropancreatic Neuroendocrine Tumors to Boost Market
6.4 Radium-223 Dichloride
6.4.1 Increasing Adoption of Radium-223 Dichloride in Emerging Markets to Stimulate Growth
6.5 Lu-177 Pnt2002
6.5.1 Strong Phase Iii Clinical Validation and Strategic Commercialization Partnerships to Spur Growh
6.6 ²²5Ac-Psma-617
6.6.1 Potent Therapeutic Profile and Expanding Clinical Validation to Bolster Growth
6.7 Fpi-2265
6.7.1 Early Response Data and Safety Reassurance to Amplify Growth
6.8 I-131-1095
6.8.1 Favorable Dosimetry and Safety Profiles to Sustain Growth
6.9 Tlx591
6.9.1 Simplified Dosing Regimen and Favorable Tolerability to Drive Market
6.10 Alphamedix ( ²¹²Pb-Dotamtate)
6.10.1 Robust Early-Phase Efficacy and Strong Commercialization to Support Growth
6.11 67Cu-Sar-Bispsma
6.11.1 Enhanced Lesion Uptake & Retention and Favorable Tolerability Profile to Foster Growth
6.12 Other Products

7.1 Introduction
7.2 Prostate-Specific Membrane Antigen
7.2.1 Strong Biological Rationale, Robust Clinical Outcomes, and Rapid Scaling of Global Supply Chains to Promote Growth
7.3 Somatostatin Receptor
7.3.1 Proven Efficacy in Treating Neuroendocrine Tumors to Expedite Growth
7.4 Other Targets

8.1 Introduction
8.2 Prostate Cancer
8.2.1 Expanding Treatment Populations and Clinical Validation to Encourage Growth
8.3 Neuroendocrine Tumors
8.3.1 Regulatory Advancements and Strategic Industry Moves to Facilitate Growth
8.4 Other Indications

9.1 Introduction
9.2 Tertiary Care Academic/Comprehensive Cancer Centers
9.2.1 Advanced Treatment Delivery and Clinical Trial Capabilities to Contribute to Growth
9.3 Specialized Nuclear Medicine Centers
9.3.1 Highly Trained Personnel and Targeted Facilities to Accelerate Growth
9.4 Other End-users

10.1 Introduction
10.2 North America
10.2.1 Macroeconomic Outlook for North America
10.2.2 US
10.2.2.1 Robust Ecosystem of Biotech Innovation and Strong Academic-Industry Collaboration to Spur Growth.
10.2.3 Canada
10.2.3.1 Growing Clinical Trial Momentum to Drive Market
10.3 Europe
10.3.1 Macroeconomic Outlook for Europe
10.3.2 Germany
10.3.2.1 Strong Clinical Advancements and Active Industry Partnerships to Foster Growth.
10.3.3 UK
10.3.3.1 Growing Efforts for Decentralized Access and Innovations to Boost Market
10.3.4 France
10.3.4.1 Strong Nuclear Medicine Manufacturing and Isotope Supply Foundation to Bolster Growth
10.3.5 Italy
10.3.5.1 Rising Preclinical Exploration and Early Discovery Stages to Stimulate Growth
10.3.6 Spain
10.3.6.1 Established Nuclear-Medicine Departments and Authorized Radiopharmacy Frameworks to Aid Growth
10.3.7 Rest of Europe
10.4 Asia-Pacific
10.4.1 Macroeconomic Outlook for Asia-Pacific
10.4.2 China
10.4.2.1 Favorable Regulatory Reforms and Expanding Hospital-Based Nuclear Medicine Capabilities to Amplify Growth
10.4.3 Japan
10.4.3.1 Academic Excellence, Manufacturing Expansion, and Supportive Regulation to Contribute to Growth
10.4.4 India
10.4.4.1 Lower Trial Costs and Skilled Medical Professionals to Accelerate Growth
10.4.5 South Korea
10.4.5.1 Growing Emphasis on Nuclear Medicine Innovation to Propel Market
10.4.6 Australia
10.4.6.1 Need to Maintain High Standards of Quality, Compliance, and Innovation to Facilitate Growth
10.4.7 Rest of Asia-Pacific
10.5 Latin America
10.5.1 Macroeconomic Outlook for Latin America
10.5.2 Brazil
10.5.2.1 Favorable Educational Initiatives and Expanding Biopharma Infrastructure to Promote Growth
10.5.3 Mexico
10.5.3.1 Growing Cyclotron Capacity to Fuel Market
10.5.4 Rest of Latin America
10.6 Middle East
10.6.1 Macroeconomic Outlook for Middle East
10.6.2 Gcc Countries
10.6.3 Saudi Arabia
10.6.3.1 Growing Initiatives for Healthcare and Life Sciences Sectors to Drive Market
10.6.4 Uae
10.6.4.1 Emerging Biotechnology Sector to Intensify Growth
10.6.5 Rest of Gcc Countries
10.6.6 Rest of Middle East
10.7 Africa
10.7.1 Enhanced Clinical Trial Ecosystem and Regulatory Reforms to Aid Growth
10.7.2 Macroeconomic Outlook for Africa

11.1 Introduction
11.2 Key Player Strategies/Right to Win
11.3 Overview of Strategies Adopted by Key Players
11.4 Revenue Analysis, 2028-2030
11.5 Market Share Analysis, 2030
11.6 Company Valuation and Financial Metrics
11.7 Brand/Product Comparison
11.8 Company Evaluation Matrix: Key Players, 2024
11.8.1 Stars
11.8.2 Emerging Leaders
11.8.3 Pervasive Players
11.8.4 Participants
11.8.5 Company Footprint: Key Players, 2024
11.8.5.1 Region Footprint
11.8.5.2 Target Footprint
11.8.5.3 Indication Footprint
11.9 Company Evaluation Matrix: Startups/Smes, 2024
11.9.1 Progressive Companies
11.9.2 Responsive Companies
11.9.3 Dynamic Companies
11.9.4 Starting Blocks
11.9.5 Competitive Benchmarking: Startups/Smes, 2024
11.9.5.1 Detailed List of Key Startups/Smes
11.9.5.2 Competitive Benchmarking of Key Startups/Smes
11.10 Competitive Scenario
11.10.1 Product Launches and Approvals
11.10.2 Deals
11.10.3 Expansions

12.1 Key Players
12.1.1 Novartis AG
12.1.1.1 Business Overview
12.1.1.2 Products Offered
12.1.1.3 Products in Pipeline
12.1.1.4 Recent Developments
12.1.1.4.1 Product Launches and Approvals
12.1.1.4.2 Deals
12.1.1.4.3 Expansions
12.1.1.5 Publisher View
12.1.1.5.1 Key Strengths
12.1.1.5.2 Strategic Choices
12.1.1.5.3 Weaknesses and Competitive Threats
12.1.2 Bayer AG
12.1.2.1 Business Overview
12.1.2.2 Products Offered
12.1.2.2.1 Deals
12.1.2.2.2 Other Developments
12.1.2.3 Publisher View
12.1.2.3.1 Key Strengths
12.1.2.3.2 Strategic Choices
12.1.2.3.3 Weaknesses and Competitive Threats
12.1.3 Curium US LLC
12.1.3.1 Business Overview
12.1.3.2 Products in Pipeline
12.1.3.3 Recent Developments
12.1.3.3.1 Deals
12.1.3.4 Publisher View
12.1.3.4.1 Key Strengths
12.1.3.4.2 Strategic Choices
12.1.3.4.3 Weaknesses and Competitive Threats
12.1.4 Eli Lilly and Company
12.1.4.1 Business Overview
12.1.4.2 Products in Pipeline
12.1.4.3 Recent Developments
12.1.4.3.1 Product Launches and Approvals
12.1.4.3.2 Deals
12.1.4.4 Publisher View
12.1.4.4.1 Key Strengths
12.1.4.4.2 Strategic Choices
12.1.4.4.3 Weaknesses and Competitive Threats
12.1.5 Astrazeneca
12.1.5.1 Business Overview
12.1.5.2 Products in Pipeline
12.1.5.3 Recent Developments
12.1.5.3.1 Deals
12.1.5.4 Publisher View
12.1.5.4.1 Key Strengths
12.1.5.4.2 Strategic Choices
12.1.5.4.3 Weaknesses and Competitive Threats
12.1.6 Progenics Pharmaceuticals Inc. (Lantheus)
12.1.6.1 Business Overview
12.1.6.2 Products in Pipeline
12.1.6.3 Recent Developments
12.1.6.3.1 Deals
12.1.7 Ariceum Therapeutics
12.1.7.1 Products in Pipeline
12.1.7.2 Recent Developments
12.1.7.2.1 Deals
12.1.8 Telix Pharmaceuticals
12.1.8.1 Business Overview
12.1.8.2 Products in Pipeline
12.1.8.3 Recent Developments
12.1.8.3.1 Deals
12.1.8.3.2 Expansions
12.1.8.3.3 Other Developments
12.1.9 Itm Isotope Technologies
12.1.9.1 Business Overview
12.1.9.2 Products Offered
12.1.9.3 Recent Developments
12.1.9.3.1 Deals
12.1.9.3.2 Expansions
12.1.10 Convergent Therapeutics, Inc.
12.1.10.1 Business Overview
12.1.10.2 Products in Pipeline
12.1.10.3 Recent Developments
12.1.10.3.1 Product Launches and Approvals
12.1.10.3.2 Deals
12.1.11 Orano Sa
12.1.11.1 Business Overview
12.1.11.2 Products in Pipeline
12.1.11.3 Recent Developments
12.1.11.3.1 Deals
12.1.11.3.2 Expansions
12.1.12 Actinium Pharmaceuticals, Inc.
12.1.12.1 Business Overview
12.1.12.2 Products in Pipeline
12.1.12.3 Recent Developments
12.1.12.3.1 Product Launches and Approvals
12.1.12.3.2 Deals
12.1.13 Perspective Therapeutics, Inc.
12.1.13.1 Business Overview
12.1.13.2 Products in Pipeline
12.1.13.3 Recent Developments
12.1.13.3.1 Deals
12.1.14 Clarity Pharmaceuticals
12.1.14.1 Business Overview
12.1.14.2 Products in Pipeline
12.1.14.3 Recent Developments
12.1.14.3.1 Deals
12.1.14.3.2 Other Developments
12.1.15 Radiopharm Theranostics Ltd.
12.1.15.1 Business Overview
12.1.15.2 Products in Pipeline
12.1.15.3 Recent Developments
12.1.15.3.1 Deals
12.2 Other Players
12.2.1 Alpha 9 Oncology
12.2.2 Ratio Therapeutics
12.2.3 Noria Therapeutics
12.2.4 Precirix
12.2.5 Sofie
12.2.6 Eckert & Ziegler Radiopharma
12.2.7 Northstar Medical Radioisotopes, LLC
12.2.8 Ire- Ire Elit
12.2.9 Bwxt Medical Ltd.
12.2.10 Ntp Radioisotopes

13.1 Discussion Guide
13.2 Knowledgestore: Subscription Portal
13.3 Customization Options
13.4 Related Reports
13.5 Author Details

Table 1 Radioligand Therapy Market: Inclusions and Exclusions
Table 2 Impact Analysis of Supply-Side and Demand-Side Factors
Table 3 Radioligand Therapy Market: Risk Analysis
Table 4 Pharmaceutical Contract Manufacturing Market, for Radiopharmaceutical Molecules by Region, 2023-2030 (USD Billion)
Table 5 Radioligand Therapy Market: Impact Analysis of Market Dynamics
Table 6 Indicative Pricing Analysis of Radioligand Therapy Products, by Key Player, 2024
Table 7 Indicative Pricing Analysis of Radioligand Therapy Products, By Region, 2024
Table 8 Radioligand Therapy Market: Role of Companies in Ecosystem
Table 9 Radioligand Therapy Market: Key Conferences and Events, 2025-2027
Table 10 North America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 11 Europe: Regulatory Bodies, Government Agencies, and Other Organizations
Table 12 Asia-Pacific: Regulatory Bodies, Government Agencies, and Other Organizations
Table 13 Rest of the World: Regulatory Bodies, Government Agencies, and Other Organizations
Table 14 Radioligand Therapy Market: Porter’S Five Forces Analysis
Table 15 Influence of Stakeholders on Buying Process of Radioligand Therapy Products (%)
Table 16 Key Buying Criteria for Radioligand Therapy, by End-user
Table 17 Health Expenditure and Financing, 2015-2024 (In Percentage of Gdp)
Table 18 US: Cancer Incidence, by State, 2024
Table 19 Radioligand Therapy Products in Clinical Pipeline, 2025-2032
Table 20 US-Adjusted Reciprocal Tariff Rates
Table 21 Radioligand Therapy Market, by Product, 2023-2035 (USD Million)
Table 22 Radioligand Therapy Market for Lutetium-177 Vipivotide Tetraxetan, By Region, 2023-2035 (USD Million)
Table 23 North America: Radioligand Therapy Market for Lutetium-177 Vipivotide Tetraxetan, by Country, 2023-2035 (USD Million)
Table 24 Europe: Radioligand Therapy Market for Lutetium-177 Vipivotide Tetraxetan, by Country, 2023-2035 (USD Million)
Table 25 Asia-Pacific: Radioligand Therapy Market for Lutetium-177 Vipivotide Tetraxetan, by Country, 2023-2035 (USD Million)
Table 26 Latin America: Radioligand Therapy Market for Lutetium-177 Vipivotide Tetraxetan, by Country, 2023-2035 (USD Million)
Table 27 Middle East: Radioligand Therapy Market for Lutetium-177 Vipivotide Tetraxetan, by Region, 2023-2035 (USD Million)
Table 28 Gcc Countries: Radioligand Therapy Market for Lutetium-177 Vipivotide Tetraxetan, by Country, 2023-2035 (USD Million)
Table 29 Radioligand Therapy Market for Lutetium-177 Dotatate, by Region, 2023-2035 (USD Million)
Table 30 North America: Radioligand Therapy Market for Lutetium-177 Dotatate, by Country, 2023-2035 (USD Million)
Table 31 Europe: Radioligand Therapy Market for Lutetium-177 Dotatate, By Country, 2023-2035 (USD Million)
Table 32 Asia-Pacific: Radioligand Therapy Market for Lutetium-177 Dotatate, By Country, 2023-2035 (USD Million)
Table 33 Latin America: Radioligand Therapy Market for Lutetium-177 Dotatate, by Country, 2023-2035 (USD Million)
Table 34 Middle East: Radioligand Therapy Market for Lutetium-177 Dotatate, By Region, 2023-2035 (USD Million)
Table 35 Gcc Countries: Radioligand Therapy Market for Lutetium-177 Dotatate, by Country, 2023-2035 (USD Million)
Table 36 Radioligand Therapy Market for Radium-223 Dichloride, by Region, 2023-2035 (USD Million)
Table 37 North America: Radioligand Therapy Market for Radium-223 Dichloride, by Country, 2023-2035 (USD Million)
Table 38 Europe: Radioligand Therapy Market for Radium-223 Dichloride, By Country, 2023-2035 (USD Million)
Table 39 Asia-Pacific: Radioligand Therapy Market for Radium-223 Dichloride, By Country, 2023-2035 (USD Million)
Table 40 Latin America: Radioligand Therapy Market for Radium-223 Dichloride, by Country, 2023-2035 (USD Million)
Table 41 Middle East: Radioligand Therapy Market for Radium-223 Dichloride, by Region, 2023-2035 (USD Million)
Table 42 Gcc Countries: Radioligand Therapy Market for Radium-223 Dichloride, by Country, 2023-2035 (USD Million)
Table 43 Radioligand Therapy Market for Lu-177 Pnt2002, by Region, 2023-2035 (USD Million)
Table 44 North America: Radioligand Therapy Market for Lu-177 Pnt2002, By Country, 2023-2035 (USD Million)
Table 45 Europe: Radioligand Therapy Market for Lu-177 Pnt2002, by Country, 2023-2035 (USD Million)
Table 46 Asia-Pacific: Radioligand Therapy Market for Lu-177 Pnt2002, By Country, 2023-2035 (USD Million)
Table 47 Latin America: Radioligand Therapy Market for Lu-177 Pnt2002, By Country, 2023-2035 (USD Million)
Table 48 Middle East: Radioligand Therapy Market for Lu-177 Pnt2002, By Region, 2023-2035 (USD Million)
Table 49 Gcc Countries: Radioligand Therapy Market for Lu-177 Pnt2002, By Country, 2023-2035 (USD Million)
Table 50 Radioligand Therapy Market for ²²5Ac-Psma-617, by Region, 2023-2035 (USD Million)
Table 51 North America: Radioligand Therapy Market for ²²5Ac-Psma-617, By Country, 2023-2035 (USD Million)
Table 52 Europe: Radioligand Therapy Market for ²²5Ac-Psma-617, by Country, 2023-2035 (USD Million)
Table 53 Asia-Pacific: Radioligand Therapy Market for ²²5Ac-Psma-617, By Country, 2023-2035 (USD Million)
Table 54 Latin America: Radioligand Therapy Market for ²²5Ac-Psma-617,0 by Country, 2023-2035 (USD Million)
Table 55 Middle East: Radioligand Therapy Market for ²²5Ac-Psma-617, by Region, 2023-2035 (USD Million)
Table 56 Gcc Countries: Radioligand Therapy Market for ²²5Ac-Psma-617, By Country, 2023-2035 (USD Million)
Table 57 Radioligand Therapy Market for Fpi-2265, by Region, 2023-2035 (USD Million)
Table 58 North America: Radioligand Therapy Market for Fpi-2265, by Country, 2023-2035 (USD Million)
Table 59 Europe: Radioligand Therapy Market for Fpi-2265, by Country, 2023-2035 (USD Million)
Table 60 Asia-Pacific: Radioligand Therapy Market for Fpi-2265, by Country, 2023-2035 (USD Million)
Table 61 Latin America: Radioligand Therapy Market for Fpi-2265, by Country, 2023-2035 (USD Million)
Table 62 Middle East: Radioligand Therapy Market for Fpi-2265, by Region, 2023-2035 (USD Million)
Table 63 Gcc Countries: Radioligand Therapy Market for Fpi-2265, by Country, 2023-2035 (USD Million)
Table 64 Radioligand Therapy Market for I-131-1095, by Region, 2023-2035 (USD Million)
Table 65 North America: Radioligand Therapy Market for I-131-1095, by Country, 2023-2035 (USD Million)
Table 66 Europe: Radioligand Therapy Market for I-131-1095, by Country, 2023-2035 (USD Million)
Table 67 Asia-Pacific: Radioligand Therapy Market for I-131-1095, by Country, 2023-2035 (USD Million)
Table 68 Latin America: Radioligand Therapy Market for I-131-1095, by Country, 2023-2035 (USD Million)
Table 69 Middle East: Radioligand Therapy Market for I-131-1095, by Region, 2023-2035 (USD Million)
Table 70 Gcc Countries: Radioligand Therapy Market for I-131-1095, by Country, 2023-2035 (USD Million)
Table 71 Radioligand Therapy Market for Tlx591, by Region, 2023-2035 (USD Million)
Table 72 North America: Radioligand Therapy Market for Tlx591, by Country, 2023-2035 (USD Million)
Table 73 Europe: Radioligand Therapy Market for Tlx591, by Country, 2023-2035 (USD Million)
Table 74 Asia-Pacific: Radioligand Therapy Market for Tlx591, by Country, 2023-2035 (USD Million)
Table 75 Latin America: Radioligand Therapy Market for Tlx591, by Country, 2023-2035 (USD Million)
Table 76 Middle East: Radioligand Therapy Market for Tlx591, by Region, 2023-2035 (USD Million)
Table 77 Gcc Countries: Radioligand Therapy Market for Tlx591, by Country, 2023-2035 (USD Million)
Table 78 Radioligand Therapy Market for ²¹²Pb-Dotamtate, by Region, 2023-2035 (USD Million)
Table 79 North America: Radioligand Therapy Market for ²¹²Pb-Dotamtate, By Country, 2023-2035 (USD Million)
Table 80 Europe: Radioligand Therapy Market for ²¹²Pb-Dotamtate, by Country, 2023-2035 (USD Million)
Table 81 Asia-Pacific: Radioligand Therapy Market for ²¹²Pb-Dotamtate, By Country, 2023-2035 (USD Million)
Table 82 Latin America: Radioligand Therapy Market for ²¹²Pb-Dotamtate, By Country, 2023-2035 (USD Million)
Table 83 Middle East: Radioligand Therapy Market for ²¹²Pb-Dotamtate, By Region, 2023-2035 (USD Million)
Table 84 Gcc Countries: Radioligand Therapy Market for ²¹²Pb-Dotamtate, By Country, 2023-2035 (USD Million)
Table 85 Radioligand Therapy Market for 67Cu-Sar-Bispsma, by Region, 2023-2035 (USD Million)
Table 86 North America: Radioligand Therapy Market for 67Cu-Sar-Bispsma, By Country, 2023-2035 (USD Million)
Table 87 Europe: Radioligand Therapy Market for 67Cu-Sar-Bispsma, by Country, 2023-2035 (USD Million)
Table 88 Asia-Pacific: Radioligand Therapy Market for 67Cu-Sar-Bispsma, By Country, 2023-2035 (USD Million)
Table 89 Latin America: Radioligand Therapy Market for 67Cu-Sar-Bispsma, By Country, 2023-2035 (USD Million)
Table 90 Middle East: Radioligand Therapy Market for 67Cu-Sar-Bispsma, By Region, 2023-2035 (USD Million)
Table 91 Gcc Countries: Radioligand Therapy Market for 67Cu-Sar-Bispsma, By Country, 2023-2035 (USD Million)
Table 92 Radioligand Therapy Market for Other Products, by Region, 2023-2035 (USD Million)
Table 93 North America: Radioligand Therapy Market for Other Products, By Country, 2023-2035 (USD Million)
Table 94 Europe: Radioligand Therapy Market for Other Products, by Country, 2023-2035 (USD Million)
Table 95 Asia-Pacific: Radioligand Therapy Market for Other Products, By Country, 2023-2035 (USD Million)
Table 96 Latin America: Radioligand Therapy Market for Other Products, By Country, 2023-2035 (USD Million)
Table 97 Middle East: Radioligand Therapy Market for Other Products, By Region, 2023-2035 (USD Million)
Table 98 Gcc Countries: Radioligand Therapy Market for Other Products, By Country, 2023-2035 (USD Million)
Table 99 Radioligand Therapy Market, by Target, 2023-2035 (USD Million)
Table 100 Radioligand Therapy Market for Prostate-Specific Membrane Antigen, by Region, 2023-2035 (USD Million)
Table 101 North America: Radioligand Therapy Market for Prostate-Specific Membrane Antigen, by Country, 2023-2035 (USD Million)
Table 102 Europe: Radioligand Therapy Market for Prostate-Specific Membrane Antigen, by Country, 2023-2035 (USD Million)
Table 103 Asia-Pacific: Radioligand Therapy Market for Prostate-Specific Membrane Antigen, by Country, 2023-2035 (USD Million)
Table 104 Latin America: Radioligand Therapy Market for Prostate-Specific Membrane Antigen, by Country, 2023-2035 (USD Million)
Table 105 Middle East: Radioligand Therapy Market for Prostate-Specific Membrane Antigen, by Region, 2023-2035 (USD Million)
Table 106 Gcc Countries: Radioligand Therapy Market for Prostate-Specific Membrane Antigen, by Country, 2023-2035 (USD Million)
Table 107 Radioligand Therapy Market for Somatostatin Receptor, by Region, 2023-2035 (USD Million)
Table 108 North America: Radioligand Therapy Market for Somatostatin Receptor, by Country, 2023-2035 (USD Million)
Table 109 Europe: Radioligand Therapy Market for Somatostatin Receptor, By Country, 2023-2035 (USD Million)
Table 110 Asia-Pacific: Radioligand Therapy Market for Somatostatin Receptor, by Country, 2023-2035 (USD Million)
Table 111 Latin America: Radioligand Therapy Market for Somatostatin Receptor, by Country, 2023-2035 (USD Million)
Table 112 Middle East: Radioligand Therapy Market for Somatostatin Receptor, by Region, 2023-2035 (USD Million)
Table 113 Gcc Countries: Radioligand Therapy Market for Somatostatin Receptor, by Country, 2023-2035 (USD Million)
Table 114 Radioligand Therapy Market for Other Targets, by Region, 2023-2035 (USD Million)
Table 115 North America: Radioligand Therapy Market for Other Targets, By Country, 2023-2035 (USD Million)
Table 116 Europe: Radioligand Therapy Market for Other Targets, by Country, 2023-2035 (USD Million)
Table 117 Asia-Pacific: Radioligand Therapy Market for Other Targets, By Country, 2023-2035 (USD Million)
Table 118 Latin America: Radioligand Therapy Market for Other Targets, By Country, 2023-2035 (USD Million)
Table 119 Middle East: Radioligand Therapy Market for Other Targets, by Region, 2023-2035 (USD Million)
Table 120 Gcc Countries: Radioligand Therapy Market for Other Targets, By Region, 2023-2035 (USD Million)
Table 121 Radioligand Therapy Market, by Indication, 2023-2035 (USD Million)
Table 122 Radioligand Therapy Market for Prostate Cancer, by Region, 2023-2035 (USD Million)
Table 123 North America: Radioligand Therapy Market for Prostate Cancer, By Country, 2023-2035 (USD Million)
Table 124 Europe: Radioligand Therapy Market for Prostate Cancer, by Country, 2023-2035 (USD Million)
Table 125 Asia-Pacific: Radioligand Therapy Market for Prostate Cancer, By Country, 2023-2035 (USD Million)
Table 126 Latin America: Radioligand Therapy Market for Prostate Cancer, By Country, 2023-2035 (USD Million)
Table 127 Middle East: Radioligand Therapy Market for Prostate Cancer, By Region, 2023-2035 (USD Million)
Table 128 Gcc Countries: Radioligand Therapy Market for Prostate Cancer, By Country, 2023-2035 (USD Million)
Table 129 Radioligand Therapy Market for Neuroendocrine Tumors, by Region, 2023-2035 (USD Million)
Table 130 North America: Radioligand Therapy Market for Neuroendocrine Tumors, by Country, 2023-2035 (USD Million)
Table 131 Europe: Radioligand Therapy Market for Neuroendocrine Tumors, By Country, 2023-2035 (USD Million)
Table 132 Asia-Pacific: Radioligand Therapy Market for Neuroendocrine Tumors, by Country, 2023-2035 (USD Million)
Table 133 Latin America: Radioligand Therapy Market for Neuroendocrine Tumors, by Country, 2023-2035 (USD Million)
Table 134 Middle East: Radioligand Therapy Market for Neuroendocrine Tumors, by Region, 2023-2035 (USD Million)
Table 135 Gcc Countries: Radioligand Therapy Market for Neuroendocrine Tumors, by Country, 2023-2035 (USD Million)
Table 136 Radioligand Therapy Market for Other Indications, by Region, 2023-2035 (USD Million)
Table 137 North America: Radioligand Therapy Market for Other Indications, By Country, 2023-2035 (USD Million)
Table 138 Europe: Radioligand Therapy Market for Other Indications, by Country, 2023-2035 (USD Million)
Table 139 Asia-Pacific: Radioligand Therapy Market for Other Indications, By Country, 2023-2035 (USD Million)
Table 140 Latin America: Radioligand Therapy Market for Other Indications, By Country, 2023-2035 (USD Million)
Table 141 Middle East: Radioligand Therapy Market for Other Indications, By Region, 2023-2035 (USD Million)
Table 142 Gcc Countries: Radioligand Therapy Market for Other Indications, By Country, 2023-2035 (USD Million)
Table 143 Radioligand Therapy Market, by End-user, 2023-2035 (USD Million)
Table 144 Radioligand Therapy Market for Tertiary Care Academic/Comprehensive Cancer Centers, by Region, 2023-2035 (USD Million)
Table 145 North America: Radioligand Therapy Market for Tertiary Care Academic/Comprehensive Cancer Centers, by Country, 2023-2035 (USD Million)
Table 146 Europe: Radioligand Therapy Market for Tertiary Care Academic/Comprehensive Cancer Centers, by Country, 2023-2035 (USD Million)
Table 147 Asia-Pacific: Radioligand Therapy Market for Tertiary Care Academic/Comprehensive Cancer Centers, by Country, 2023-2035 (USD Million)
Table 148 Latin America: Radioligand Therapy Market for Tertiary Care Academic/Comprehensive Cancer Centers, by Country, 2023-2035 (USD Million)
Table 149 Middle East: Radioligand Therapy Market for Tertiary Care Academic/Comprehensive Cancer Centers, by Region, 2023-2035 (USD Million)
Table 150 Gcc Countries: Radioligand Therapy Market for Tertiary Care Academic/Comprehensive Cancer Centers, by Country, 2023-2035 (USD Million)
Table 151 Radioligand Therapy Market for Specialized Nuclear Medicine Centers, by Region, 2023-2035 (USD Million)
Table 152 North America: Radioligand Therapy Market for Specialized Nuclear Medicine Centers, by Country, 2023-2035 (USD Million)
Table 153 Europe: Radioligand Therapy Market for Specialized Nuclear Medicine Centers, by Country, 2023-2035 (USD Million)
Table 154 Asia-Pacific: Radioligand Therapy Market for Specialized Nuclear Medicine Centers, by Country, 2023-2035 (USD Million)
Table 155 Latin America: Radioligand Therapy Market for Specialized Nuclear Medicine Centers, by Country, 2023-2035 (USD Million)
Table 156 Middle East: Radioligand Therapy Market for Specialized Nuclear Medicine Centers, by Region, 2023-2035 (USD Million)
Table 157 Gcc Countries: Radioligand Therapy Market for Specialized Nuclear Medicine Centers, by Country, 2023-2035 (USD Million)
Table 158 Radioligand Therapy Market for Other End-users, by Region, 2023-2035 (USD Million)
Table 159 North America: Radioligand Therapy Market for Other End-users, By Country, 2023-2035 (USD Million)
Table 160 Europe: Radioligand Therapy Market for Other End-users, by Country, 2023-2035 (USD Million)
Table 161 Asia-Pacific: Radioligand Therapy Market for Other End-users, By Country, 2023-2035 (USD Million)
Table 162 Latin America: Radioligand Therapy Market for Other End-users, By Country, 2023-2035 (USD Million)
Table 163 Middle East: Radioligand Therapy Market for Other End-users, By Region, 2023-2035 (USD Million)
Table 164 Gcc Countries: Radioligand Therapy Market for Other End-users, By Country, 2023-2035 (USD Million)
Table 165 Radioligand Therapy Market, by Region, 2023-2035 (USD Million)
Table 166 North America: Key Macroeconomic Indicators
Table 167 North America: Radioligand Therapy Market, by Country, 2023-2035 (USD Million)
Table 168 North America: Radioligand Therapy Market, by Product, 2023-2035 (USD Million)
Table 169 North America: Radioligand Therapy Market, by Target, 2023-2035 (USD Million)
Table 170 North America: Radioligand Therapy Market, by Indication, 2023-2035 (USD Million)
Table 171 North America: Radioligand Therapy Market, by End-user, 2023-2035 (USD Million)
Table 172 US: Radioligand Therapy Market, by Product, 2023-2035 (USD Million)
Table 173 US: Radioligand Therapy Market, by Target, 2023-2035 (USD Million)
Table 174 US: Radioligand Therapy Market, by Indication, 2023-2035 (USD Million)
Table 175 US: Radioligand Therapy Market, by End-user, 2023-2035 (USD Million)
Table 176 Canada: Radioligand Therapy Market, by Product, 2023-2035 (USD Million)
Table 177 Canada: Radioligand Therapy Market, by Target, 2023-2035 (USD Million)
Table 178 Canada: Radioligand Therapy Market, by Indication, 2023-2035 (USD Million)
Table 179 Canada: Radioligand Therapy Market, by End-user, 2023-2035 (USD Million)
Table 180 Europe: Key Macroeconomic Indicators
Table 181 Europe: Radioligand Therapy Market, by Country, 2023-2035 (USD Million)
Table 182 Europe: Radioligand Therapy Market, by Product, 2023-2035 (USD Million)
Table 183 Europe: Radioligand Therapy Market, by Target, 2023-2035 (USD Million)
Table 184 Europe: Radioligand Therapy Market, by Indication, 2023-2035 (USD Million)
Table 185 Europe: Radioligand Therapy Market, by End-user, 2023-2035 (USD Million)
Table 186 Germany: Radioligand Therapy Market, by Product, 2023-2035 (USD Million)
Table 187 Germany: Radioligand Therapy Market, by Target, 2023-2035 (USD Million)
Table 188 Germany: Radioligand Therapy Market, by Indication, 2023-2035 (USD Million)
Table 189 Germany: Radioligand Therapy Market, by End-user, 2023-2035 (USD Million)
Table 190 UK: Radioligand Therapy Market, by Product, 2023-2035 (USD Million)
Table 191 UK: Radioligand Therapy Market, by Target, 2023-2035 (USD Million)
Table 192 UK: Radioligand Therapy Market, by Indication, 2023-2035 (USD Million)
Table 193 UK: Radioligand Therapy Market, by End-user, 2023-2035 (USD Million)
Table 194 France: Radioligand Therapy Market, by Product, 2023-2035 (USD Million)
Table 195 France: Radioligand Therapy Market, by Target, 2023-2035 (USD Million)
Table 196 France: Radioligand Therapy Market, by Indication, 2023-2035 (USD Million)
Table 197 France: Radioligand Therapy Market, by End-user, 2023-2035 (USD Million)
Table 198 Italy: Radioligand Therapy Market, by Product, 2023-2035 (USD Million)
Table 199 Italy: Radioligand Therapy Market, by Target, 2023-2035 (USD Million)
Table 200 Italy: Radioligand Therapy Market, by Indication, 2023-2035 (USD Million)
Table 201 Italy: Radioligand Therapy Market, by End-user, 2023-2035 (USD Million)
Table 202 Spain: Radioligand Therapy Market, by Product, 2023-2035 (USD Million)
Table 203 Spain: Radioligand Therapy Market, by Target, 2023-2035 (USD Million)
Table 204 Spain: Radioligand Therapy Market, by Indication, 2023-2035 (USD Million)
Table 205 Spain: Radioligand Therapy Market, by End-user, 2023-2035 (USD Million)
Table 206 Rest of Europe: Radioligand Therapy Market, by Product, 2023-2035 (USD Million)
Table 207 Rest of Europe: Radioligand Therapy Market, by Target, 2023-2035 (USD Million)
Table 208 Rest of Europe: Radioligand Therapy Market, by Indication, 2023-2035 (USD Million)
Table 209 Rest of Europe: Radioligand Therapy Market, by End-user, 2023-2035 (USD Million)

Figure 1 Radioligand Therapy Market Segmentation and Regional Scope
Figure 2 Radioligand Therapy Market: Years Considered
Figure 3 Radioligand Therapy Market: Research Design
Figure 4 Radioligand Therapy Market: Key Data from Secondary Sources
Figure 5 Radioligand Therapy Market: Breakdown of Primary Interviews
Figure 6 Radioligand Therapy Market Size Estimation (Supply-Side Analysis), 2024
Figure 7 Company Revenue Analysis-Based Estimation: Bottom-Up Approach, 2030
Figure 8 Revenue Share Analysis of Novartis, 2024
Figure 9 Radioligand Therapy Market Size Validation from Primary Sources
Figure 10 Radioligand Therapy Market: Top-Down Approach
Figure 11 Radioligand Therapy Market: CAGR Projections
Figure 12 Radioligand Therapy Market: Data Triangulation
Figure 13 Radioligand Therapy Market: Global Market Size, Growth Rate, and Forecast
Figure 14 Radioligand Therapy Market, by Product, 2025 Vs. 2035 (USD Million)
Figure 15 Radioligand Therapy Market, by Target, 2025 Vs. 2035 (USD Million)
Figure 16 Radioligand Therapy Market, by Indication, 2025 Vs. 2035 (USD Million)
Figure 17 Radioligand Therapy Market, by End-user, 2025 Vs. 2035 (USD Million)
Figure 18 Geographical Snapshot of Radioligand Therapy Market
Figure 19 Increasing Approvals and Label Expansion of Rlt Products To Drive Market
Figure 20 Lutetium-177 Vipivotide Tetraxetan Segment and US to Lead North American Market in 2024
Figure 21 China to Register Highest Growth During Forecast Period
Figure 22 Developed Markets to Register Higher Growth Rate During Forecast Period
Figure 23 Radioligand Therapy Market: Drivers, Restraints, Opportunities, And Challenges
Figure 24 New Revenue Pockets for Players in Radioligand Therapy Market
Figure 25 Indicative Pricing Analysis of Radioligand Therapy Products, By Key Player, 2024
Figure 26 Indicative Pricing Analysis, by Region, 2024
Figure 27 Radioligand Therapy Market: Value Chain Analysis
Figure 28 Radioligand Therapy Market: Ecosystem Analysis
Figure 29 Radioligand Therapy Market: Investment and Funding Scenario, 2023-2024
Figure 30 Radioligand Therapy Market: Porter’S Five Forces Analysis
Figure 31 Influence of Stakeholders on Buying Process of Radioligand Therapy Products
Figure 32 Key Buying Criteria for Radioligand Therapy Products, by End-user
Figure 33 Radioligand Therapy Market: AI Use Cases
Figure 34 North America: Radioligand Therapy Market Snapshot
Figure 35 Asia-Pacific: Radioligand Therapy Market Snapshot
Figure 36 Radioligand Therapy Market: Revenue Analysis of Key Players, 2028-2030 (USD Million)
Figure 37 Radioligand Therapy Market Share Analysis of Key Players, 2030
Figure 38 Ev/Ebitda of Key Vendors
Figure 39 Year-To-Date (Ytd) Price Total Return and 5-Year Stock Beta of Key Vendors
Figure 40 Radioligand Therapy Market: Brand/Product Comparison
Figure 41 Radioligand Therapy Market: Company Evaluation Matrix (Key Players), 2024
Figure 42 Radioligand Therapy Market: Company Footprint
Figure 43 Radioligand Therapy Market: Company Evaluation Matrix (Startups/Smes), 2024
Figure 44 Novartis AG: Company Snapshot (2024)
Figure 45 Bayer AG: Company Snapshot (2024)
Figure 46 Eli Lilly and Company: Company Snapshot (2024)
Figure 47 Astrazeneca: Company Snapshot (2024)
Figure 48 Progenics Pharmaceutical Inc. (Lantheus): Company Snapshot (2024)
Figure 49 Telix Pharmaceuticals: Company Snapshot (2024)
Figure 50 Orano Sa: Company Snapshot (2024)
Figure 51 Actinium Pharmaceuticals, Inc.: Company Snapshot (2023)
Figure 52 Clarity Pharmaceuticals: Company Snapshot (2024)